CAPLIPOINT · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 57/100 — Quality 90 · Valuation 6 · Growth 75 · Momentum 34
| Share price | ₹2,649.20 |
| Market cap | ₹12,945 Cr |
| P/E ratio | 21.1 |
| P/B ratio | 4.2 |
| ROCE | 23.3% |
| Dividend yield | 0.35% |
| Book value | ₹405.84 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹2,187 Cr | ₹650 Cr | 35.0% |
| 2025 | ₹1,937 Cr | ₹541 Cr | 34.0% |
| 2024 | ₹1,694 Cr | ₹461 Cr | 33.0% |
| 2023 | ₹1,467 Cr | ₹377 Cr | 30.0% |
| 2022 | ₹1,269 Cr | ₹308 Cr | 31.0% |
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point